Sugi Predict

Sugi Predict / Compounds / SCHEMBL1706284

SCHEMBL1706284

SCHEMBL1706284

Cc1ccnc(Nc2ccc3cccc(Br)c3n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KARS1 Q15046 9/20 0.48
▸ KDR P35968 2/20 0.45
▸ MAP4K4 O95819 1/20 0.45
▸ ABL1 P00519 1/20 0.45
▸ LCK P06239 1/20 0.45
▸ FYN P06241 1/20 0.45
▸ IGF1R P08069 1/20 0.45
▸ LTK P29376 1/20 0.45
▸ MAP2K2 P36507 1/20 0.45
▸ MAPK8 P45983 1/20 0.45
▸ MAPK9 P45984 1/20 0.45
▸ CLK2 P49760 1/20 0.45
▸ GSK3A P49840 1/20 0.45
▸ GSK3B P49841 1/20 0.45
▸ CDK7 P50613 1/20 0.45
▸ CDK9 P50750 1/20 0.45
▸ CDK5 Q00535 1/20 0.45
▸ MAP2K1 Q02750 1/20 0.45
▸ ACVR1 Q04771 1/20 0.45
▸ PTK2 Q05397 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1702521 0.86 KARS1 (0.50) KARS1KDRMAP4K4ABL1LCK
SCHEMBL1702275 0.83 MDM2 (0.48) KARS1KDRMAP4K4ABL1LCK
SCHEMBL1702151 0.83 KARS1 (0.48) KARS1KDRMAP4K4ABL1LCK
SCHEMBL1702193 0.83 KARS1 (0.54) KARS1KDRMAP4K4ABL1LCK
Hydrochloric Acid SCHEMBL13518353 0.82 MDM2 (0.47) KARS1KDRMAP4K4ABL1LCK
SCHEMBL1702471 0.81 NPC1 (0.48) KARS1KDRMAP4K4ABL1LCK
SCHEMBL22134945 0.80 SMN1; SMN2 (0.68) KDRKMT2ANPC1RAB9AKDM4E
SCHEMBL1702126 0.78 ALDH1A1 (0.51) KARS1KMT2ANPC1RAB9ALMNA
SCHEMBL901321 0.78 KARS1 (0.57) KARS1KDRMAP4K4ABL1LCK
SCHEMBL1702487 0.77 KMT2A (0.47) KARS1KDRMAPK8MAPK9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440546-B1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA ABIVAX (FR) 2022-12-28 — — EP claimed
EP-2440547-B1 New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects ABIVAX (FR) 2022-11-30 — — EP claimed
EP-2440545-B1 COMPOUNDS USEFUL FOR TREATING CANCER ABIVAX (FR) 2019-04-24 — — EP claimed
US-9908869-B2 Compounds useful for treating aids ABIVAX (FR) 2018-03-06 — — US claimed
US-9827237-B2 Compounds useful for treating diseases caused by retroviruses ABIVAX (FR) 2017-11-28 — — US claimed
US-20160151348-A1 COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES ABIVAX (FR) 2016-06-02 — — US claimed
EP-3016656-A1 BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES ABIVAX (FR) 2016-05-11 — — EP claimed
US-9108919-B2 Compounds useful for treating cancer ABIVAX (FR) 2015-08-18 — — US claimed
WO-2015001518-A1 BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES SPLICOS (FR) 2015-01-08 — — WO claimed
US-20140288120-A1 COMPOUNDS USEFUL FOR TREATING AIDS SOCIETE SPLICOS (FR) 2014-09-25 — — US claimed
US-20120329796-A1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA SOCIETE SPLICOS (FR) 2012-12-27 — — US claimed
US-20120283265-A1 COMPOUNDS USEFUL FOR TREATING AIDS SOCIETE SPLICOS (FR) 2012-11-08 — — US claimed
US-20120277230-A1 COMPOUNDS USEFUL FOR TREATING CANCER SOCIETE SPLICOS (FR) 2012-11-01 — — US claimed
CN-102625804-A Compounds for the treatment of AIDS SPLICOS SOC 2012-08-01 — — CN claimed
CN-102596935-A Compounds for the treatment of premature aging and especially premature aging SPLICOS SOC 2012-07-18 — — CN claimed
CN-102574835-A Compounds for the treatment of cancer SPLICOS SOC 2012-07-11 — — CN claimed
EP-2440545-A2 COMPOUNDS USEFUL FOR TREATING CANCER Société Splicos (FR) 2012-04-18 — — EP claimed
WO-2010143169-A2 COMPOUNDS USEFUL FOR TREATING AIDS SOCIÉTÉ SPLICOS (FR) 2010-12-16 — — WO claimed
WO-2010143170-A2 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA SOCIÉTÉ SPLICOS (FR) 2010-12-16 — — WO claimed
WO-2010143168-A2 COMPOUNDS USEFUL FOR TREATING CANCER SOCIÉTÉ SPLICOS (FR) 2010-12-16 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283265-A1 COMPOUNDS USEFUL FOR TREATING AIDS CBR1, CNR1, CBR3 KARS1 2583/4885KDR 4012/4885MAP4K4 3720/4885
US-20140288120-A1 COMPOUNDS USEFUL FOR TREATING AIDS NR1H3, NR3C1, NR3C2 KARS1 2525/4885KDR 2656/4885MAP4K4 3257/4885
US-20120277230-A1 COMPOUNDS USEFUL FOR TREATING CANCER CBR1, CBR3, NCOR1 KARS1 3186/4885KDR 3134/4885MAP4K4 3770/4885
US-20120329796-A1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA NR2C2, NCOR2, NR4A2 KARS1 3789/4885KDR 4279/4885MAP4K4 4064/4885
US-20160151348-A1 COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES RCOR1, CBR1, RCOR3 KARS1 1748/4885KDR 3700/4885MAP4K4 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.